Last reviewed · How we verify
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
Details
| Lead sponsor | Wenbin Wei |
|---|---|
| Status | UNKNOWN |
| Enrolment | 1000 |
| Start date | Sat Jan 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon May 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neovascular Age-related Macular Edema
- Diabetic Macular Edema
- Choroidal Neovascular Membrane
- Non-proliferative Diabetic Retinopathy
- Retinal Vein Occlusion
- Proliferative Diabetic Retinopathy
Interventions
- Ranibizumab
- Aflibercept
- Conbercept
Countries
China